Purpose: The frequency of drug administration errors and incompatibilities between intravenous drugs before ... the use of an idle i.v. line for infusion whenever possible. In the prospective ...
The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...
is a brand-name intravenous (IV) infusion prescribed to treat COVID-19 in certain adults and children. As with other drugs, Veklury can cause side effects, such as nausea and increased liver enzymes.
Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...
A prediction for 2025 by Marci Chodroff, M.D., vice president of Medical Affairs at Prime Therapeutics and Managed Healthcare ...
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...
Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for ...
About the Insignis Infusion System The Insignis Syringe Infusion System is a robust, non-electric device designed for routine ...